Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis (Nasdaq: PSNL) will release its first quarter 2026 financial results on Thursday, May 7, 2026. A conference call and webcast will be held the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Domestic dial-in is 877-451-6152, international dial-in is 201-389-0879, and a live webinar and replay will be available via the Events section at investors.personalis.com.
Personalis (NASDAQ: PSNL) presented multiple clinical and real-world datasets at AACR 2026 showing the NeXT Personal ctDNA assay's ultrasensitive MRD performance and a new resistance-tracking feature. Key metrics include a median limit of detection of 1.92 PPM, 100% sensitivity/specifity/NPV in select cohorts, and a >99.9% specificity for resistance calls.
Data cover neoadjuvant colorectal cancer, a 10,000-patient real-world cohort, resistance mutation tracking, and NSCLC immunotherapy stratification, highlighting potential clinical utility for monitoring response, relapse risk, and emerging resistance.
Personalis (Nasdaq: PSNL) will present NeXT Personal ultrasensitive ctDNA data and debut a new MRD option, Real-Time Variant Tracker, at AACR 2026 in San Diego April 17–22. Presentations include an oral podium on April 20 and three posters highlighting ESR1 resistance tracking and detection sensitivity below 100 ppm and 10 ppm.
The Real-Time Variant Tracker is described as a first-of-its-kind tumor-informed feature to longitudinally monitor therapy resistance mutations during MRD testing.
Personalis (Nasdaq: PSNL) said its management will participate in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. The company is expected to discuss corporate strategy and recent developments in advanced genomics for precision oncology.
Personalis (Nasdaq: PSNL) promoted Richard Chen, M.D., M.S., to President while he continues as Chief Medical Officer, effective March 17, 2026.
The move unifies R&D, biopharma services, reimbursement, quality systems and medical affairs to accelerate commercial adoption of the NeXT Personal ultrasensitive MRD testing platform and scale revenue growth.
Personalis (Nasdaq: PSNL) announced publication of the PREDICT-DNA study in Journal of Clinical Oncology showing NeXT Personal ultrasensitive ctDNA testing improves neoadjuvant treatment monitoring in breast cancer.
The prospective study of 227 TNBC and HER2+ patients across 24+ US centers found ctDNA status post-NAT strongly predicted relapse risk and risk-stratified patients beyond pCR and nodal status.
Personalis (Nasdaq: PSNL) reported 2025 results and 2026 guidance. Full year 2025 revenue was $69.6M versus $84.6M in 2024; clinical test volume rose nearly 400% to 16,233 tests. The company ended 2025 with approximately $240M cash.
Personalis secured Medicare coverage for breast and lung cancer surveillance, expects 2026 revenue of $78–$80M, clinical revenue of $10–$11M, 43,000–45,000 clinical tests, and projected net loss of $105M.
Personalis (Nasdaq: PSNL) said its management team will attend the TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.
The appearance is a management attendance at a sector conference and does not announce new financial or clinical data.
Personalis (Nasdaq: PSNL) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and live webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Investors can join by phone (877-451-6152 domestic; 201-389-0879 international) or watch the live webinar via the Events section at investors.personalis.com. A replay will be archived on the website after the call.
Personalis (Nasdaq: PSNL) announced that Medicare will cover its NeXT Personal molecular residual disease (MRD) test for surveillance of Stage I–III non-small cell lung cancer. Coverage is supported by data from the TRACERx collaboration, with results published in Cell, and expands access for Medicare beneficiaries.
The test uses whole-genome sequencing and tracks up to ~1800 mutations to detect trace circulating tumor DNA (ctDNA) for earlier recurrence surveillance.